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Combined Use of Laser Capture Microdissection
and cDNA Microarray Analysis Identifies Locally
Expressed Disease-Related Genes in Focal Regions
of Psoriasis Vulgaris Skin Lesions
Hiroshi Mitsui1, Mayte Sua´rez-Farin˜as1,2, Daniel A. Belkin3, Natasha Levenkova2,4,
Judilyn Fuentes-Duculan1, Israel Coats1, Hideki Fujita1 and James G. Krueger1
Psoriasis vulgaris is a complex disease characterized by alterations in growth and differentiation of epidermal
keratinocytes, as well as a marked increase in leukocyte populations. Lesions are known to contain alterations in
messenger RNAs encoding more than 1,000 products, but only a very small number of these transcripts has
been localized to specific cell types or skin regions. In this study, we used laser capture microdissection (LCM)
and gene array analysis to study the gene expression of cells in lesional epidermis (EPI) and dermis, compared
with the corresponding non-lesional regions. Using this approach, we detected41,800 differentially expressed
gene products in the EPI or dermis of psoriasis lesions. These results established sets of genes that are
differentially expressed between epidermal and dermal compartments, as well as between non-lesional and
lesional psoriasis skin. One of our findings involved the local production of CCL19, a lymphoid-organizing
chemokine, and its receptor CCR7 in psoriatic dermal aggregates, along with the presence of gene products
LAMP3/DC-LAMP and CD83, which typify mature dendritic cells (DCs). Gene expression patterns obtained with
LCM and microarray analysis along with T-cell and DC detection by immune staining suggest a possible
mechanism for lymphoid organization via CCL19/CCR7 in diseased skin.
Journal of Investigative Dermatology (2012) 132, 1615–1626; doi:10.1038/jid.2012.33; published online 8 March 2012
INTRODUCTION
Valuable insights into the pathogenic processes of various
skin diseases can be obtained by studying differentially
expressed genes (DEGs) via complementary DNA (cDNA)
microarray analysis. However, whole-tissue analysis has
limitations, including its inability to localize messenger RNAs
(mRNAs) to specific cell types. In addition, gene products
specific to ‘‘minority’’ cell types may be lost by dilution
with mRNAs from more dominant cell types. Our group
developed cellular genomic maps of the skin by using in vitro
cultured cells of various types to localize in vivo gene
changes to specific cell types (Haider et al., 2008). However,
there are important differences between cultured cells and
their in vivo counterparts. For example, keratinocytes under-
go two differentiation programs in vivo—homeostatic growth
and regenerative maturation—whereas cultured keratino-
cytes reflect predominantly the regenerative phenotype
(Mansbridge and Knapp, 1987; Kennedy-Crispin et al.,
2012). In addition, cultured keratinocytes are less differen-
tiated than their in vivo counterparts. Inflammatory skin
diseases such as psoriasis and atopic dermatitis also contain
several types of dendritic cells (DCs) that cannot be found in
normal skin and blood, and are distinct from those differen-
tiated from monocytes in vitro with specific cytokines.
Given that psoriasis vulgaris is a complex disease
involving distinct cells and tissues (marked alterations in
growth, differentiation, and patterning of the epidermis (EPI),
as well as tissue infiltration by T cells, DCs, and other
myeloid leukocytes), it would be desirable to localize
disease-related genes specifically to the EPI or immune
components. Numerous prior studies have used bulk
tissue homogenates to establish major differences in
gene expression between diseased and non-diseased states
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Although specific studies differ in the total number of DEGs,
the psoriasis transcriptome has consistent alterations in
41,000 transcripts between lesional and non-lesional skin.
Only a relatively small number of DEGs has been localized to
specific cells or regions of psoriasis lesions in prior studies,
e.g., by immune staining for protein products.
We therefore sought to expand our understanding of cell/
region-specific molecular changes in psoriasis vulgaris
through the use of laser capture microdissection (LCM)
combined with cDNA microarray analysis. LCM is a
technique used to isolate subpopulations of cells from tissue
sections under direct microscopic visualization (Espina et al.,
2006), but its application to gene expression analysis has
been limited by the difficulty of recovering sufficient amounts
of RNA for whole-transcriptome analysis (Cle´ment-Ziza et al.,
2009). There has also been the concern that multiple-
amplified mRNA products may not reflect the correct
abundance of transcripts as detected by single amplification
methods used in whole-tissue analysis. We chose to perform
regional gene expression analysis on psoriasis, because (1)
prior bulk tissue studies provide a strong reference gene set
for comparison with LCM-derived transcripts, and (2) distinct
cellular and genomic pathways should exist within epidermal
and dermal/immune tissue compartments. Our results estab-
lished marked differences in gene expression between the EPI
and dermis of non-lesional psoriasis skin, as well as between
the diseased EPI and dermis of lesional skin. Specifically,
leukocyte-rich dermal inflammatory regions in psoriasis
lesions contained high-level expression of a number of
genes, as well as corresponding proteins, that direct
lymphoid organization and structure. This suggests a mechan-
ism for the formation and persistence of T-cell-mediated
inflammation in diseased skin. Extensive experiments pre-
sented in Supplementary results and discussion online (SRD)
evaluate potential technical limitations of LCM methodology
that must be considered before it can be applied widely to
other skin diseases.
RESULTS
LCM localizes genes selectively expressed in non-lesional EPI
and dermis
We performed LCM to collect cells in the EPI, papillary
dermis, reticular dermis (RD), and dermal inflammatory
cell aggregates (ICs) in frozen sections of the skin, as shown
in Supplementary Figure S1c and d online. The potential
quality of RNA of our samples and the efficacy of the
double amplification are summarized in Supplementary
Figure S1a, b, and e online. We also assessed the linearity
of double amplification in Supplementary Figure S1f online.
The PCA plot and heat map (Supplementary Figure S2a and b
online) illustrating unsupervised clustering of expression
values for all samples clearly show that there are
no outliers, and that the major source of variation
in the samples is the sample type (i.e., EPI, Dermis,
and Bulk), even when samples from the same patient are
used.
To evaluate the specificity of LCM to localize gene
products, we compared gene expression profiles of EPI and
RD in non-lesional skin. In EPI, 1,151 probe sets were
upregulated and 1,471 were downregulated. Table 1a and b
show the top 25 upregulated and downregulated DEGs,
respectively. Known keratinocyte-related genes such as
KRT1, KRT2, KRT5, DSC1, and DSC3, as well as melano-
cyte-related genes TYRP1 and DCT, were found in EPI. In RD,
we found higher expression of collagens (COL3A1 and
COL6A3), immune-related genes (CXCL12, IGHA1, and
LYZ), and vascular endothelial cell and leukocyte transen-
dothelial migration–related genes (SPARCL1, PECAM1, and
VCAM1). We can thus clearly separate gene expression in
different regions of the skin combining LCM and cDNA
microarray analysis. The complete list of DEGs between EPI
and RD of non-lesional skin is shown in Supplementary Table
S1 online.
LCM localizes disease-related DEGs in psoriasis EPI
Gene expression profiles between lesional and non-lesional
EPI samples were compared. Table 2a and b present the top
25 upregulated and downregulated genes in the EPI-related
psoriasis transcriptome, respectively. Upregulated genes
include those related to hyperproliferation (KRT6A, KRT6B,
and KRT16), epidermal differentiation complex (S100 family
proteins and small proline-rich proteins), and proteolysis
regulation molecules (SERPINs and PI3). These results are
consistent with previous works using bulk tissue samples, but
earlier studies were not able to specify the cells with altered
gene expression. Among downregulated genes, we examined
the protein expression of CRIP-1 and CCL27 (Table 2b) using
immunohistochemistry (IHC). Both proteins were detected
in non-lesional EPI but were decreased in lesional EPI,
confirming our microarray results (Figure 1a and b).
We also focused our attention on transcription factors (TFs)
identified in the EPI transcriptome. TFs that are considered to
be involved in keratinocyte proliferation (NFE2L3,MAFF, and
EHF) were upregulated in lesional EPI, whereas those thought
to be involved in keratinocyte differentiation (LASS6,
TFAP2B, and GATA3) were downregulated. The complete
lists of EPI transcriptome and TFs are found in Supplementary
Tables S2 and S3 online.
LCM localizes genes selectively expressed in ICs of psoriasis
lesions
Psoriasis lesions contain dense aggregates of LAMP3/DC-
LAMPþ DCs, marking mature DCs, that are intermixed with
T cells in the dermis, but gene expression in this ‘‘lymphoid’’
area has not been investigated. Table 3 presents the top 25
upregulated genes in RD/ICs. Interestingly, 6 of the 25 were
genes encoding chemokines or chemokine receptors, includ-
ing CCL19 and its receptor CCR7. Genes associated with
immune response, such as LAMP3/DC-LAMP, CD28, GZMB,
and CD83, are also on this list. The complete list is available
in Supplementary Table S4 online.
Confirmation by quantitative reverse-transcribe PCR (qRT-
PCR) for EPI and RD transcriptomes were performed on six
specific mRNAs as shown in Supplementary Figure S3a
1616 Journal of Investigative Dermatology (2012), Volume 132
H Mitsui et al.
Mapping Gene Expression in Skin Regions
Table 1. Short lists of DEGs in psoriasis non-lesional EPI versus non-lesional RD (LCM)1
Probe set ID FCH FDR Symbol Description
(a) Top 25 upregulated genes in psoriasis non-lesional EPI versus non-lesional RD
205900_at 252.28 o0.01 KRT1 Keratin 1
205694_at 244.41 o0.01 TYRP1 Tyrosinase-related protein 1
207908_at 243.36 o0.01 KRT2 Keratin 2
206400_at 153.37 0.01 LGALS7/7B Lectin, galactoside binding, soluble, 7/7B
206032_at 139.60 0.02 DSC3 Desmocollin 3
207324_s_at 130.69 o0.01 DSC1 Desmocollin 1
204379_s_at 92.21 o0.01 FGFR3 Fibroblast growth factor receptor 3
207955_at 91.10 o0.01 CCL27 Chemokine (C–C motif) ligand 27
213506_at 88.21 o0.01 F2RL1 Coagulation factor II (thrombin) receptor-like 1
201131_s_at 82.44 0.01 CDH1 Cadherin 1, type 1, E-cadherin (epithelial)
207109_at 81.63 o0.01 POU2F3 POU class 2 homeobox 3
204455_at 78.56 0.01 DST Dystonin
221854_at 76.68 o0.01 PKP1 Plakophilin 1
213929_at 70.43 0.01 EXPH5 Exophilin 5
206276_at 66.07 o0.01 LY6D Lymphocyte antigen 6 complex, locus D
205337_at 64.29 0.01 DCT Dopachrome tautomerase
209570_s_at 63.15 o0.01 D4S234E DNA segment on chromosome 4—234 expressed sequence
206642_at 58.40 0.01 DSG1 Desmoglein 1
205807_s_at 57.30 o0.01 TUFT1 Tuftelin 1
219995_s_at 55.76 o0.01 ZNF750 Zinc finger protein 750
204469_at 50.94 0.01 PTPRZ1 Protein tyrosine phosphatase, receptor type, Z polypeptide 1
204653_at 49.93 0.01 TFAP2A Transcription factor AP-2 a
217528_at 49.02 0.08 CLCA2 Chloride channel accessory 2
217744_s_at 47.24 0.03 PERP PERP, TP53 apoptosis effector
201820_at 46.26 0.03 KRT5 Keratin 5
(b) Top 25 downregulated genes in psoriasis non-lesional EPI versus non-lesional RD
209687_at 250.00 o0.01 CXCL12 Chemokine (C–X–C motif) ligand 12
217022_s_at 250.00 o0.01 IGHA1 Ig heavy constant a 1
200795_at 200.00 o0.01 SPARCL1 SPARC-like 1 (hevin)
215388_s_at 166.67 o0.01 CFH/CFHR1 Complement factor H/complement factor H-related 1
213975_s_at 166.67 o0.01 LYZ Lysozyme (renal amyloidosis)
217757_at 142.86 o0.01 A2M a 2-Macroglobulin
215076_s_at 125.00 0.01 COL3A1 Collagen, type III, a 1
208982_at 125.00 o0.01 PECAM1 Platelet/endothelial cell-adhesion molecule
209613_s_at 111.11 o0.01 ADH1B Alcohol dehydrogenase 1B(class I), b polypeptide
213800_at 111.11 o0.01 CFH Complement factor H
206201_s_at 111.11 o0.01 MEOX2 Mesenchyme homeobox 2
208335_s_at 90.91 o0.01 DARC Duffy blood group, chemokine receptor
222043_at 83.33 o0.01 CLU Clusterin
202291_s_at 83.33 o0.01 MGP Matrix Gla protein
219777_at 76.92 o0.01 GIMAP6 GTPase, IMAP family member 6
Table 1 continued on following page
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online. There is a high correlation between differential
expressions detected by the double amplification–based
microarray and qRT-PCR (r¼ 0.87, P¼0.0002, Supplemen-
tary Figure S3b online).
Protein expression of detected genes in dermal aggregates was
confirmed by IHC and immunofluorescent staining
To further confirm the differential expression of certain
targets, tissue sections were examined by IHC.
STAT1 stained in the cytosol of cells in non-lesional EPI
and in the nucleus of cells in lesional EPI. In addition,
STAT1þ cells were increased in lesional dermis compared
with non-lesional dermis (Figure 1c). CCR7 and CCL19 both
stained in dermal aggregates of lesional skin (Figure 1d and
e). CCL21, another ligand for CCR7, was not detected by
IHC, consistent with our microarray data, where expression
of CCL21 was quite low. CXCL13/BCA-1 was detected in
lesional dermis (Figure 1g). CXCR5, a receptor for CXCL13/
BCA-1, and CD20, a B-cell marker, were also positive in
lesional dermis (Figure 1h and i). Collectively, differences in
gene expression of these molecules obtained from microarray
analysis using LCM samples correlated very well to differ-
ences in their protein expression in tissues.
To further explore the nature of chemokines and relevant
receptors in skin tissues, we performed double-label im-
munofluorescence. CCR7 and CCL19 were expressed in close
proximity in lesional dermal aggregates (Figure 2a). CCR7 co-
stained with LAMP3/DC-LAMP and the T-cell marker CD3
(Figure 2b and c). CCL19 co-stained with myeloid DC marker
CD11c, LAMP3/DC-LAMP, and CD3 (Figure 2d–f). CXCL13/
BCA-1 and CXCR5 were also expressed in close proximity in
lesional dermal aggregates (Figure 2g). CXCR5þ cells co-
stained with CD20 (Figure 2h). These results demonstrate that
dermal aggregates in psoriasis, mainly composed of DCs, T cells,
and to a lesser degree B cells were associated with the
coordinated expression of lymph node–organizing chemo-
kines and their receptors.
LCM detects more DEGs than bulk tissue analysis
For more detailed discussion, please refer to SRD section 2
(Supplementary Figures S2, S5–S8 and Tables S7–S9
online). The psoriasis transcriptome, defined as the DEGs
between lesional and non-lesional samples using fold change
(FCH)42.0 and false discovery rate (FDR)o0.1 cutoffs, was
determined for bulk skin samples (psoriatic transcriptome
(psDEGs)-Bulk), laser-captured EPI (psDEGs-EPI), and laser-
captured RD (psDEGs-RD), which tends to include ICs in
lesional samples. psDEGs-Bulk contained 155/58 (upregu-
lated/downregulated) probe sets (Supplementary Table S5
online). psDEGs-EPI contained 815/631 probe sets (Supple-
mentary Table S2 online), and psDEGs-RD contained 309/
181 probe sets (Supplementary Table S4 online). The psDEG
for papillary dermis was not defined because of an
insufficient amount of RNA obtained from non-lesional
papillary dermis (Supplementary Figure S1c online). Scatter
plots show positive correlations between log2FCH of Bulk
and those of EPI and RD (Figure 3a and b). Correlation
between Bulk and EPI was higher (r¼0.68, Po1 1016)
than that between Bulk and RD (r¼0.31, Po1 1016),
suggesting a greater contribution of EPI-related genes than
RD-related genes in Bulk analysis. Importantly, trend lines
(red lines in Figure 3a and b) were shifted toward larger FCH
in LCM samples compared with Bulk samples. In fact,
76.47% of probe sets with absolute FCH42.0 in both EPI
and Bulk showed higher FCH in EPI than Bulk, and for RD it
was 58.61% (Figure 3c and Supplementary Figure S2d online,
see SRD section 2-i). These results may reflect the overall
increase in DEGs detected via LCM compared with bulk
tissue analysis (Figure 3d and e). We acknowledge that, as we
expected, many fewer genes were detected in our Bulk
analysis compared with previously published studies that had
larger patient cohorts (n¼ 26, Yao et al., 2008; n¼15,
Sua´rez-Farin˜as et al., 2010; n¼ 58, Gudjonsson et al., 2010,
see a discussion of the effect of sample size in SRD section
2-ii, Supplementary Figures S6–S8 online). We further compared
Table 1. Continued
Probe set ID FCH FDR Symbol Description
201744_s_at 76.92 0.01 LUM Lumican
212950_at 71.43 o0.01 GPR116 G-protein-coupled receptor 116
204115_at 62.50 o0.01 GNG11 Guanine nucleotide–binding protein (G-protein), g 11
218353_at 62.50 o0.01 RGS5 Regulator of G-protein signaling 5
203868_s_at 62.50 o0.01 VCAM1 Vascular cell adhesion molecule 1
221731_x_at 62.50 o0.01 VCAN Versican
201438_at 58.82 o0.01 COL6A3 Collagen, type VI, a 3
217028_at 58.82 o0.01 CXCR4 Chemokine (C–X–C motif) receptor 4
202404_s_at 55.56 0.01 COL1A2 Collagen, type I, a 2
202404_s_at 55.56 0.01 NR2F2 Nuclear receptor subfamily 2, group F, member 2
Abbreviations: DEG, differentially expressed gene; EPI, epidermis; FCH, fold change; FDR, false discovery rate; LCM, laser capture microdissection;
RD, reticular dermis.
1The probe set ID whose fold change was largest was listed when multiple probe sets were available for same gene. Unannotated genes were excluded from
the top 25 gene list.
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Table 2. Short lists of DEGs in psoriasis lesional EPI versus non-lesional EPI (LCM)1
EPI (LCM) Bulk
Probe set ID Symbol FCH FDR FCH FDR Description
(a) Top 25 upregulated genes in psoriasis lesional EPI versus non-lesional EPI
211906_s_at SERPINB4 470.72 o0.01 419.60 o0.01 Serpin peptidase inhibitor, clade B member 4
209720_s_at SERPINB3 366.10 o0.01 171.61 o0.01 Serpin peptidase inhibitor, clade B member 3
203535_at S100A9 136.52 o0.01 106.56 o0.01 S100 calcium–binding protein A9
203691_at PI3 128.03 o0.01 67.67 o0.01 Peptidase inhibitor 3, skin derived
207356_at DEFB4 114.24 o0.01 69.88 o0.01 Defensin, b 4
205916_at S100A7 84.37 o0.01 10.67 0.21 S100 calcium–binding protein A7 (psoriasin)
213680_at KRT6B 67.99 o0.01 3.61 0.54 Keratin 6B
205863_at S100A12 57.07 o0.01 32.81 o0.01 S100 calcium–binding protein A12
209125_at KRT6A 55.71 o0.01 18.77 0.02 Keratin 6A
217272_s_at SERPINB13 55.50 o0.01 8.13 o0.01 Serpin peptidase inhibitor, clade B member 13
220322_at IL1F9 55.34 o0.01 19.15 o0.01 IL 1 family, member 9 (IL-36 gamma)
206488_s_at CD36 53.72 o0.01 1.80 0.30 CD36molecule
202917_s_at S100A8 50.84 0.03 53.07 0.14 S100 calcium–binding protein A8
205513_at TCN1 50.11 o0.01 39.15 o0.01 Transcobalamin I
219795_at SLC6A14 47.10 o0.01 5.84 0.13 Solute carrier family 6 member 14
206177_s_at ARG1 46.24 o0.01 3.57 0.07 Arginase, liver
220664_at SPRR2C 45.97 o0.01 32.99 o0.01 Small proline-rich protein 2C
213796_at SPRR1A 35.17 o0.01 6.03 0.24 Small proline-rich protein 1A
208650_s_at CD24 29.72 o0.01 7.49 o0.01 CD24molecule
206643_at HAL 24.28 o0.01 5.42 o0.01 Histidine ammonia-lyase
207381_at ALOX12B 22.66 o0.01 4.59 o0.01 Arachidonate 12-lipoxygenase, 12R type
209800_at KRT16 21.75 o0.01 16.48 0.02 Keratin 16
201242_s_at ATP1B1 21.33 o0.01 2.46 0.57 ATPase, Na+/K+ transporting, b 1 polypeptide
206561_s_at AKR1B10 20.04 o0.01 20.14 o0.01 Aldo-keto reductase family 1, member B10
213060_s_at CHI3L2 19.97 o0.01 5.46 o0.01 Chitinase 3-like 2
(b) Top 25 downregulated genes in psoriasis lesional EPI versus non-lesional EPI
210809_s_at POSTN 62.50 o0.01 1.44 0.35 Periostin, osteoblast specific factor
205081_at CRIP1 20.41 o0.01 2.48 0.17 Cysteine-rich protein 1 (intestinal)
214598_at CLDN8 15.38 o0.01 4.57 0.08 Claudin 8
201540_at FHL1 9.80 o0.01 1.88 0.35 Four and a half LIM domains 1
219087_at ASPN 9.52 o0.01 1.79 0.50 Asporin
215516_at LAMB4 9.17 o0.01 1.98 o0.01 Laminin, b 4
201843_s_at EFEMP1 8.85 o0.01 1.89 0.22 EGF containing fibulin-like extracellular matrix protein1
213369_at PCDH21 8.26 o0.01 2.26 0.07 Protocadherin 21
202746_at ITM2A 7.87 o0.01 2.35 0.03 Integral membrane protein 2A
206170_at ADRB2 7.52 o0.01 2.95 0.01 Adrenergic, b-2-, receptor, surface
209292_at ID4 7.41 o0.01 3.06 0.06 Inhibitor of DNA binding 4
207955_at CCL27 7.25 0.01 3.38 0.21 Chemokine (C–C motif) ligand 27
202973_x_at FAM13A 7.25 o0.01 1.76 0.07 Family with sequence similarity 13, member A
201506_at TGFBI 7.04 o0.01 1.72 0.13 Transforming growth factor, b-induced, 68 kDa
215239_x_at ZNF273 6.85 o0.01 2.29 0.28 Zinc finger protein 273
Table 2 continued on following page
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our uniquely detected genes in EPI (644 upregulated and
586 downregulated) and RD (241 upregulated and 146
downregulated) with the psoriasis transcriptomes published
in the three studies listed above, as well as that detected by
next-generation sequencing technology (Jabbari et al., 2012).
Approximately, 50% of unique genes in EPI and 30% of
unique genes in RD were confirmed in at least one out of
the four transcriptomes (Figure 3f and g). Furthermore, we
performed RT-PCR on the top eight unique downregulated
genes (ABAT, COL4A5, CXCR7, DDB2, ERAP1, NRTN, SRPX,
and TCF4) that were not detected in the above four studies, and
we show that expression of each gene was clearly down-
regulated in our bulk tissue samples (Figure 3h). Thus, our
LCM-unique DEGs have the potential to provide many new
genes that have not previously been associated with the
psoriasis transcriptome. The complete list of LCM-unique
probe sets is provided in Supplementary Table S6 online.
DISCUSSION
By combining LCM and cDNA microarray analysis, we
sought to define gene expression within different regions of
human skin, as altered by psoriasis vulgaris. We focused on
the cellular aggregates found in psoriatic lesional dermis,
where LAMP3/DC-LAMPþ DCs have been identified along
with T cells (Zaba et al., 2009). The importance of this
aggregate structure in the pathogenesis of psoriasis is
suggested by the observations that it is not identified in
non-lesional skin and that effective treatment leads to its
disappearance (Zaba et al., 2007).
Psoriasis vulgaris contains at least two distinct subsets of
myeloid DCs: BDCA1 and BDCA1þ DCs. The BDCA1
subset includes immature/inflammatory tumor necrosis fac-
tor-a–and inducible nitric oxide synthase–producing DCs and
their distribution is rather scattered (Lowes et al., 2005).
BDCA1þ DCs are immature and do not express LAMP3/DC-
LAMP in the normal skin. However, psoriasis lesions contain
clusters of LAMP3/DC-LAMPþ DCs bearing BDCA1. We
have previously compared the gene expression profiles of
BDCA1 and BDCA1þ DCs sorted by FACS from the
psoriasis skin (Zaba et al., 2010). Although BDCA1þ DCs
are phenotypically matured compared with BDCA1 DCs
based on much greater expression of CD83, CD86, and HLA-
DR by flow cytometric analysis (Zaba et al., 2009), these
molecules were not recognized as DEGs in that study (Zaba
et al., 2010). In contrast, we were able to identify CD83,
CD86, and LAMP3/DC-LAMP as upregulated DEGs in
lesional RD/ICs. As LCM permits us to identify mature DCs,
we are thus able to study genes associated with the mature
DC subsets of psoriasis.
By using LCM, we established the ectopic expression of
CCL19 and its receptor CCR7 in the dermal cellular
aggregates of lesional skin. By using bulk tissue extracts,
Zhou et al. (2003) also detected the upregulation of CCL19
and CCL21 mRNA in psoriasis skin. However, to date, the
cells producing these key lymphoid-organizing chemokines
have not been localized in vivo. We show that CCL19
production occurs selectively within perivascular T-cell and
DC aggregates, and that it likely acts to recruit CCR7þ
(self-antigen-specific) T cells and DCs into this focus.
Approximately 80% skin-resident T cells are thought to be
CCR7 effector memory T cells (TEM) (Clark et al., 2006), and
there is a concept that CCR7þ central memory T cells (TCM)
circulate from blood to draining lymph node in order to be
activated by DCs (Clark, 2010). Our results, however,
propose that the organized aggregates in psoriatic skin
contain a sizable number of CCR7þ T cells, which would
be TCM that are normally circulating between blood and
lymph nodes. Hence, skin lesions may create the same
environment for the expansion of TEM from TCM. The concept
of lymphoid organization in lesions is supported by a
previous report showing that in transgenic mice ectopic
expression of CCL19 alone could organize functional
lymphoid structures within the pancreas (Luther et al.,
2002). With regard to DC maturation, Gillet’s group recently
Table 2. Continued
EPI (LCM) Bulk
Probe set ID Symbol FCH FDR FCH FDR Description
218804_at ANO1 6.80 o0.01 1.58 0.57 Anoctamin 1
208096_s_at COL21A1 6.71 o0.01 1.85 0.14 Collagen, type XXI, a 1
218820_at C14orf132 6.62 o0.01 2.47 0.12 Chromosome 14 open reading frame 132
217627_at ZNF573 6.25 o0.01 2.41 0.13 Zinc finger protein 573
209335_at DCN 6.21 o0.01 1.54 0.26 Decorin
221645_s_at ZNF83 5.65 o0.01 1.78 0.12 Zinc finger protein 83
214723_x_at ANKRD36 5.49 o0.01 1.53 0.58 Ankyrin repeat domain 36
220940_at ANKRD36B 5.49 o0.01 1.54 0.49 Ankyrin repeat domain 36B
203881_s_at DMD 5.46 0.02 2.10 0.54 Dystrophin
206030_at ASPA 5.41 o0.01 1.51 0.74 Aspartoacylase
Abbreviations: DEG, differentially expressed gene; EPI, epidermis; FCH, fold change; FDR, false discovery rate; LCM, laser capture microdissection.
1The probe set ID whose fold change was largest was listed when multiple probe sets were available for same gene. Unannotated genes were excluded from
the top 25 gene list.
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published that self-RNA-LL37 complexes could activate
myeloid DCs through TLR8 in vitro. Moreover, these com-
plexes were co-localized with LAMP3/DC-LAMP in psoriatic
lesional dermis (Ganguly et al., 2009). Together with our data
presented here, this suggests that DC maturation could reflect
both chemoattraction of precursors from blood and local
activation by self-RNA-LL37 complexes.
Many genes altered in the psoriatic EPI have been studied
previously with bulk gene sets. We showed a heavy
representation of EPI-related genes in Bulk analysis. How-
ever, many DEGs detected in prior studies have not been
localized to defined skin regions or specific cell types. With
LCM, we were able to successfully localize to EPI or RD 935
probe sets that were detected in at least one of the three cited
studies analyzing bulk tissues (Supplementary Figure S5a and
b online, see SRD section 2-ii). For example, CRIP-1, which is
the second largest downregulated gene in lesional EPI, has
not previously been localized to the EPI, although the
downregulation of this gene is consistent across earlier bulk
studies. We also explored major differences in the expression
of TFs between lesional and non-lesional EPI. NFE2L3 and
MAFF were upregulated in lesional EPI. NFE2L3 is a member
Non-lesional skin
CCL27
CRIP1
STAT-1
CCL21
CXCL13
CXCR5
CD20CCR7
CCL19
Lesional skin Non-lesional skin Lesional skin
Figure 1. Immunohistochemical staining patterns were correlated with complementary DNA (cDNA) microarray data. (a) CCL27 was expressed in the basal
layer of non-lesional epidermis. (b) CRIP1 was expressed in the granular layer of non-lesional epidermis. (c) STAT-1 stained in the cytosol of cells in non-lesional
epidermis, whereas it stained in the nuclei of cells in lesional epidermis and dermis. (d–f) CCR7 and CCL19 were positive in dermal aggregates in lesional skin,
whereas CCL21 was detected neither in non-lesional nor lesional skin. (g, h) CXCL13 (three out of five samples) and CXCR5 (six out of eight samples) were
detected in lesional dermis. (i) CD20þ cells (three out of five samples) were also found in lesional dermis. Arrows indicate the positive layers and cells.
Bar¼100 mm.
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of the ‘‘cap‘n’collar’’ family of TFs that dimerize with other
leucine zipper proteins, such as small Maf proteins (Kobaya-
shi et al., 1999). NFE2L2, another TF of this family, was
shown to be involved in the proliferation and KRT6
expression of forestomach keratinocytes in mice when it
dimerizes with MAFF (Motohashi et al., 2004). Although
NFE2L3 but not NFE2L2 appeared on our EPI list, NFE2L3 is
known to partially compensate for the role of NFE2L2 in mice
keratinocytes during re-epithelialization in wound healing
(Braun et al., 2002). These results suggest the possible
involvement of NFE2L3 together with MAFF in the prolifera-
tion of keratinocytes in psoriasis. In contrast, LASS6, TFAP2B,
and GATA3 were downregulated in lesional EPI. LASS6 is
involved in ceramide synthesis in mice (Mizutani et al.,
2005). TFAP2B increases cystatin A expression in normal
human keratinocytes (Takahashi et al., 2000). GATA3 is a
master TF for the differentiation of Th2 cells (Ho et al., 2009),
but it also transactivates the lipid acyltransferase gene
AGPAT5, leading to the formation of an epidermal barrier
(de Guzman Strong et al., 2006). These genes are therefore
involved in terminal differentiation of keratinocytes. This TF
gene list thus includes the key genes involved in keratinocyte
proliferation and differentiation, and reflects hyperprolifera-
tion of keratinocytes and impaired differentiation in psoriatic
EPI.
Two concerns have been raised with regard to applying
LCM to global gene expression analysis. The first is that
‘‘extreme’’ gene amplification from small mRNA amounts
obtained by LCM may bias the set of genes amplified such
that it is not representative of gene pools amplified by
conventional one-cycle method (Wang et al., 2007). The
second, which comes from a variety of cancer analyses, is
Table 3. A short list of DEGs in psoriasis lesional RD/ICs versus non-lesional RD (LCM)1
RD/ICs (LCM) Bulk
Probe set ID Symbol FCH FDR FCH FDR Description
Top 25 upregulated genes in psoriasis lesional RD/ICs versus non-lesional RD
216834_at RGS1 27.12 0.02 11.53 0.08 Regulator of G-protein signaling 1
201890_at RRM2 10.66 0.04 4.29 0.23 Ribonucleotide reductase M2
205569_at LAMP3 10.58 0.01 4.38 0.08 Lysosomal-associated membrane protein 3 (CD208)
204470_at CXCL1 8.02 0.08 3.88 0.36 Chemokine (C–X–C motif) ligand 1
203559_s_at ABP1 7.70 0.02 1.45 0.82 Amiloride-binding protein 1
209774_x_at CXCL2 7.22 o0.01 1.62 0.23 Chemokine (C–X–C motif) ligand 2
213241_at PLXNC1 7.14 o0.01 1.08 0.96 Plexin C1
220330_s_at SAMSN1 7.14 0.02 2.82 0.21 SAM domain, SH3 domain and nuclear localization signals 1
206337_at CCR7 7.10 0.01 1.75 0.38 Chemokine (C–C motif) receptor 7
209969_s_at STAT1 6.93 0.01 3.49 0.10 Signal transducer and activator of transcription 1
210072_at CCL19 6.83 o0.01 4.10 0.02 Chemokine (C–C motif) ligand 19
207165_at HMMR 6.63 0.02 2.59 0.26 Hyaluronan-mediated motility receptor
206545_at CD28 6.03 0.09 1.39 0.93 CD28 molecule
219648_at MREG 5.94 0.04 2.15 0.49 Melanoregulin
210164_at GZMB 5.83 0.03 3.00 0.21 Granzyme B
204440_at CD83 5.58 o0.01 2.10 0.03 CD83 molecule
207861_at CCL22 5.41 0.04 2.36 0.35 Chemokine (C–C motif) ligand 22
206134_at ADAMDEC1 5.33 0.01 3.54 0.04 ADAM like, decysin 1
204026_s_at ZWINT 5.05 0.03 2.37 0.26 ZW10 interactor
204714_s_at F5 5.05 0.01 1.29 0.84 Coagulation factor V
205242_at CXCL13 4.99 0.01 2.40 0.14 Chemokine (C–X–C motif) ligand 13
214023_x_at TUBB2B 4.93 0.06 1.20 0.96 Tubulin, b 2B
208103_s_at ANP32E 4.57 0.02 1.33 0.79 Acidic nuclear phosphoprotein 32 family, member E
207957_s_at PRKCB 4.53 0.04 1.34 0.86 Protein kinase C, b
204932_at TNFRSF11B 4.46 0.02 1.06 0.98 Tumor necrosis factor receptor superfamily member 11b
Abbreviations: DEG, differentially expressed gene; FCH, fold change; FDR, false discovery rate; ICs, dermal inflammatory cell aggregates; LCM, laser capture
microdissection; RD, reticular dermis.
1The probe set ID whose fold change was largest was listed when multiple probe sets were available for same gene. Unannotated genes were excluded from
the top 25 gene list.
1622 Journal of Investigative Dermatology (2012), Volume 132
H Mitsui et al.
Mapping Gene Expression in Skin Regions
that it may be difficult to derive normal cells by LCM for
comparison with pathological counterparts (Klee et al.,
2009). Both issues have been addressed in this study, and
relevant data and discussion are presented in SRD section 1.
In contrast to prior work, we found an extremely high
concordance between genes detected in psoriasis tissue using
single- and double-amplification methods (r¼0.93,
Po1 1016, Supplementary Figure S4d, Tables S10 and
S11, online). In this sense, our study was more comparable to
that using high-quality control mRNA pools (Singh et al.,
2005) than to those performing gene detection in biopsies of
human cancers (Luzzi et al., 2003; de Bruin et al., 2005; Klee
et al., 2009). The second concern with regard to the
comparison of pathological to normal cell counterparts is
well obviated by using skin, where tissue structure makes it
possible to derive intrinsically valid comparisons. We there-
fore did not detect limitations of the LCM method compared
with bulk tissue analysis. Instead, we found it to be
advantageous, providing us the ability to localize and
increase disease-related gene products to specific cells/skin
regions. Although our Bulk comparison identified a smaller
DEG set than previously published studies, we established
through statistical simulations that this was mainly because of
our study’s much smaller sample size (n¼ 3) and consequent
weaker statistical power (see SRD section 2-ii, Supplementary
Figures S6–S8). Using LCM, we identified several hundred
new DEG products in psoriatic EPIþRD that were not
detected in the three large studies, suggesting greater
CCR7 CCL19
CCR7 and CCL19
LAMP3 and CCR7
CCR7CD3 CCL19CD3
LAMP3 and CCL19
CD3 and CCR7 CD3 and CCL19
CD20 and CXCR5
CD11c and CCL19 CXCR5 and CXCL13
CXCR5CD20CCL19CCR7 LAMP3LAMP3
CD11c CXCR5CCL19 CXCL13
Figure 2. Characterization of lymphoid tissue–like structures in lesional skin. (a) Both CCR7 and CCL19 were localized in dermal aggregates of the lesional
skin. (b) LAMP3/DC-LAMP was co-expressed with CCR7. (c) CD3 was also co-expressed with CCR7. (d) CCL19 expression was detected on CD11cþ and
(e) LAMP3/DC-LAMPþ dendritic cells, (f) as well as on CD3þ T cells. We also stained CXCR5 in combination with CXCL13 and CD20. (g) Both CXCL13 and
CXCR5 stained in dermal aggregates of lesional skin and (h) CXCR5 co-stained with CD20. White arrows indicate the double-positive cells. White lines
represent epidermal–dermal junctions. Bar¼ 100 mm.
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sensitivity for detection of some gene products. Nevertheless,
the greatest advantage of this technique is the ability to study
defined cellular regions of the EPI or dermis that could not
otherwise be separated from intact skin by enzymatic or other
physical methods (Clemmesen et al., 2009).
In conclusion, we have established the validity of the
combined use of LCM and cDNA microarray technologies.
We demonstrated that this approach, while not replacing
conventional bulk tissue analysis, complements it through (1)
localization of transcripts to specific cells or regions, and (2)
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Figure 3. Unique detection of differentially expressed genes (DEGs) by laser capture microdissection (LCM) samples compared with bulk skin sample.
(a, b) Scatter plots of log2FCH (fold change) of bulk versus epidermis (EPI) and reticular dermis (RD). Black lines: identity lines; gray lines: ±2 FCH; red
lines: robust linear regression estimates. (c) Percentage of probe sets with larger absolute FCH in LCM samples than in bulk. Pink bars: all probe sets;
red bars: probe sets considering |FCH|42.0. (d, e) Venn diagrams of bulk, EPI, and RD psoriasis transcriptome. (f, g) Proportion of unique EPI-, RD-,
and bulk-related probe sets that appear in 1, 2, or 3 of the published Affymetrix studies (considering HU133A2.0 probe sets), or in the next-generation
sequencing (NGS) transcriptome. The width of each bar depicts the number in each category. (h) Reverse-transcribe PCR (RT-PCR) fold changes of the top
eight unconfirmed downregulated genes using bulk tissue samples (n¼9). FDR, false discovery rate; psDEGs, psoriatic transcriptome.
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more sensitive detection of transcripts within small regions of
tissue, particularly where dilution of transcripts associated
with ‘‘minority’’ cell populations may occur. It would be
interesting to apply this method to other conditions in which
focal cellular processes may differ; i.e, to explore cells
specific to the invasive edge of a cancer or cells of certain
appendages in the skin.
MATERIALS AND METHODS
The detailed protocols and statistical analysis are described in
Supplementary materials and methods online.
Patients and samples
Approval from the Institutional review board (The Rockefeller
University) and written informed consent were obtained from
patients before enrolling them to participate in this study. The study
was conducted in adherence with the Declaration of Helsinki
Principles. Paired lesional and non-lesional samples from seven
psoriatic patients were used. Samples from the first four patients
were used in the single- versus double-amplification comparison.
Samples from the remaining three patients were subjected to LCM.
Laser capture microdissection
LCM was performed according to the manufacturer’s protocol for the
CellCut system (Molecular Machines and Industries, Haslett, MI).
RNA extraction
Total RNA was extracted from bulk tissue homogenates, sliced
frozen tissue sections, and microdissected samples using the RNeasy
Kit (QIAGEN, Valencia, CA).
cDNA microarray analysis
Target amplification and labeling was performed according to the
Affymetrix protocols for one-cycle or two-cycle cDNA synthesis.
Two-cycle cDNA synthesis was slightly modified according to a
previous report (Kube et al., 2007). Affymetrix HGU133A2.0 arrays
(Affymetrix, Santa Clara, CA) were used. The data have been
deposited at the Gene Expression Omnibus repository (GSE26866).
qRT-PCR on LCM samples
First-strand cDNA synthesis was performed using SuperScriptIII and
Random Primers (Invitrogen, Carlsbad, CA). The resulting cDNA was
used for quantitative PCR reaction. All data were normalized to
RPLP0/hARP (Wingens et al., 1998). Primers and probes used in this
experiment are listed in Supplementary Table S12 online.
IHC and IF
Frozen skin sections were prepared and standard procedures were
used. Antibodies used in this experiment are listed in Supplementary
Table S13 online.
Statistical analysis
Microarray data were analyzed using the GeneSpring GX ver-
sion10.0 software (Agilent, Palo Alto, CA) and R/Bioconductor
packages. The Harshlight package (Sua´rez-Farin˜as et al., 2005) was
used to scan Affymetrix chips for spatial artifacts. Expression values
were obtained using the RMA procedure. Expression values were
modeled using the mixed-effect framework of Bioconductor’s limma
package. Genes with FDRo0.1 and FCH42.0 were considered as
DEGs. Probe-set distance to the 30 end of the transcriptome was
compared between single- and double-amplified samples according
to a previous report (Klee et al., 2009).
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